• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>PIMCO Municipal Income II

PIMCO Municipal Income II

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Neurology Times Provides Neurologists New Tools for Success

    Neurology Times Provides Neurologists New Tools for Success

  2. A Closer Look at CEF Duration Risk

    An examination of 10 CEFs with the highest duration risk.

  3. Year in Review: Municipal CEFs

    We take a look at 2012's municipal CEF performance, distribution cuts, mergers, and more.

  4. Genentech’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma

    Genentech’s Phase III Study of Gazyva® Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma

  5. U.S. FDA Approves IMBRUVICA® (ibrutinib) for Treatment of Waldenstrom's macroglobulinemia (WM)

    U.S. FDA Approves IMBRUVICA® (ibrutinib) for Treatment of Waldenstrom's macroglobulinemia (WM)

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.